Showing posts with label Depression. Show all posts
Showing posts with label Depression. Show all posts

Tuesday, August 3, 2010

Ketamine may be promising treatment for depression among patients with bipolar disorde

Moral of the story:  While it may sound scary, Ketamine has been used for a variety of purposes and may hold promise in an area still looking for a good drug.

Source: AMA Morning Rounds 8/3/2010


Ketamine may be promising treatment for depression among patients with bipolar disorder.

The Los Angeles Times (8/2, Roan) "Booster Shots" blog reported that the prescription medication ketamine [ketamine hydrochloride], which is "used as an anesthetic -- and used illegally as a party drug at raves -- may have a role in treating people with bipolar depression, according to astudy " published August 2 in the Archives of General Psychiatry. In a study of 18 patients, "researchers at the National Institute of Mental Health found that 71% of the bipolar patients who had not responded to other treatments, experienced significant improvement in depression symptoms after a single intravenous infusion of ketamine. Most of these patients responded within 40 minutes of receiving the drug," and the effects lasted for approximately three days.
        Time (8/3, Cloud) reports, "All patients were randomly and blindly given one 0.5 mg/kg dose of ketamine and one equal dose of placebo saline through an IV drip two weeks apart. Patients taking ketamine were significantly more likely than those on the placebo to show short-term improvement in their depression symptoms. This is crucial for bipolar patients who are in depressive crisis and at high risk of suicide: if you can give them something to block short-term suicidal impulses, you may be able to settle them -- and then treat them for long-term problems."
        "Ketamine acts on the brain's glutamatergic system, which plays a role in information processing and memory formation,"HealthDay (8/2, Preidt) reported. "Recent research suggests that dysfunction in this brain system may contribute to bipolar disorder, noted Dr. Nancy Diazgranados and colleagues at the US National Institute of Health." But, even though "ketamine has been used off-label as an experimental treatment for depression, it has not been approved by the US Food and Drug Administration for that use, according to the US National Institutes of Health." WebMD (8/2, Woznicki) also covered the study.

Wednesday, May 19, 2010

New fathers may suffer from depression

Moral of the story: Be aware of this possibility when you have a kid and address the issue if you see it arising.  Depression is a treatable condition and is perfectly normal to have arise with a new kid.

Source: AMA Morning Rounds 5/19/2010

New fathers may suffer from depression.

ABC World News (5/18, story 12, 1:15, Sawyer) reported, "We've all become a lot more sensitive to the problems of postpartum depression (PPD) in new moms." Now, however, "it turns out now that...new fathers may be suffering, too."
        USA Today (5/19, Szabo) reports that, according to a study published May 19 in the Journal of the American Medical Association, "14% of American men develop depression, either during their partner's pregnancies or in the first year after delivery." In other countries, "approximately 8% of fathers...develop the problem, according to the analysis, which included 43 studies of 28,000 people."
        The study "found that 10.4% of men experienced serious depression at some point between his partner's first trimester and one year after childbirth, more than double the depression rate for men in general," the Los Angeles Times (5/19, Roan) reports. Unfortunately, "paternal depression symptoms are much less likely to be recognized than maternal depression," because men do not become weepy or sad, and instead may display anger, irritability, or detachment from their families.
        On the front of its Personal Journal section, the Wall Street Journal (5/19, D1, Wang) reports that reasons for depression in men bear similarities to those for women, and may result from being deprived of sleep and stress between partners.
        Bloomberg News (5/19, Ostrow) reports that depression "may also occur because of changes in perceived role in life, financial stress, isolation from friends and social activities." Paternal "depression was highest in the three to six months following the baby's arrival," possibly "because family leave ends about that time, particularly in the US," the study authors from the Eastern Virginia Medical School theorized.
        According to CNN (5/19, Landau), "depression in fathers has potential negative implications for the family, and for the child's development and behavioral and emotional health," lead author James Paulson, PhD, "said. Paulson's study also found that fathers' depression tended to have an association with mothers' depression -- so when moms were more depressed, so were dads." Still, further research "is needed to determine how the two are related, as one parent's moods have not been proven to cause the other's."

Wednesday, January 6, 2010

Postmenopausal women taking antidepressants may be at higher risk for stroke, death

Moral of the story: Postmenopausal women on antidepressants are 45% more likely than those not on such medication to have a stroke, and 32% more likely to die of any cause.

AMA Morning Rounds 12/15/09

Postmenopausal women taking antidepressants may be at higher risk for stroke, death.


The Los Angeles Times (12/14, Healy) "Booster Shots" blog reported that, according to a study published in the Archives of Internal Medicine, "postmenopausal women taking antidepressants are at higher risk of suffering a stroke or of dying of any cause than are those who do not take such medications." Investigators "followed 136,293 post-menopausal women, age 50 to 79, for just under six years," during which time "5,496 developed depression and were treated with antidepressant medication." Researchers found that over the course of "follow-up, the women on antidepressants were 45% more likely than those not on such medication to have a stroke, and 32% more likely to die of any cause."
        HealthDay (12/14, Edelson) reported that while the study found that "women on selective serotonin uptake inhibitors," such as "Celexa [citalopram], Paxil [paroxetine], Prozac [fluoxetine], and Zoloft [sertraline]," as well as "tricyclic antidepressants," had an increased risk for stroke and death, "the overall risk for any one woman remained very small."

Sunday, November 29, 2009

Depression may take as many years off life as smoking.

Moral of the story: Mental illnesses are serious threats to long-term health

Source: AMA Morning Rounds 11/24/09

Depression may take as many years off life as smoking.

HealthDay (11/23, Dotinga) reported that, according to a study published in the British Journal of Psychiatry, "being depressed might take as many years off your life as smoking does." After "analyzing death records and a survey of more than 60,000 people," researchers at King's College London found that "during the four years after the survey, the death rate was higher among those who'd appeared to be depressed, based on the survey findings, than among the others," with the "increase...about as high as that among smokers." Notably, the investigators also found that "a combination of depression and anxiety appears to be better for longevity than just depression."

Wednesday, March 25, 2009

Obesity Fact or Fiction?

Moral of the story: There is a ton of information out there about obesity and being overweight. Some of it is misinformation, get the facts below. If you want links to the articles click here.

Nature: Obesity
Factor or Fiction?

FICTION: Children who are tall but heavy will eventually grow into their weight and have a healthier BMI as they age.

The Interaction of Childhood Height and Childhood BMI in the Prediction of Young Adult BMI
Steven D. Stovitz, Mark A. Pereira, Gabriela Vazquez, Leslie A. Lytle and John H. Himes
Obesity advance online publication; July 24, 2008; doi:10.1038/oby.2008.359

FACT: An estimated 17% of children and adolescents ages 2-19 years are overweight*.
*Results from 2003-2004 National Health and Nutrition Examination Survey (NHANES)

School-based Obesity Prevention Programs: An Evidence-based Review
Jonathan A. Kropski, Paul H. Keckley and Gordon L. Jensen
Obesity 16; 1009-1018; doi:10.1038/oby.2008.29

Four-year Follow-up of School-based Intervention on Overweight Children: The KOPS Study
Sandra Plachta-Danielzik, Svenja Pust, Inga Asbeck, Mareike Czerwinski-Mast, Kristina Langnäse, Carina Fischer, Anja Bosy-Westphal, Peter Kriwy and Manfred J. Müller
Obesity 15; 3159-3169; doi:10.1038/oby.2007.376

FACT: Studies have reported that up to 60% of individuals with schizophrenia and 68% of those with bipolar disorder are overweight/obese.

Impact of Obesity on Health-related Quality of Life in Schizophrenia and Bipolar Disorder
Ronette L. Kolotkin, Patricia K. Corey-Lisle, Ross D. Crosby, Jodi M. Swanson, Anne V. Tuomari, Gilbert J. L'Italien and James E. Mitchell
Obesity 16; 749-754; doi:10.1038/oby.2007.133

FICTION: Being overweight has little or no impact on calling in sick to work or school.

Relative Weight and Sickness Absence
Mikko Laaksonen, Kustaa Piha and Sirpa Sarlio-Lähteenkorva
Obesity 15; 465-472; doi:10.1038/oby.2007.55

The Relationship Between Relative Weight and School Attendance Among Elementary Schoolchildren
Andrew B. Geier, Gary D. Foster, Leslie G. Womble, Jackie McLaughlin, Kelley E. Borradaile, Joan Nachmani, Sandy Sherman, Shiriki Kumanyika, Justine Shults
Obesity 15; 2157-2161; doi:10.1038/oby.2007.256

FACT: Moving? Be careful where you settle down - unpacking your belongings in a new location may pack on extra pounds.

Neighborhood Risk Factors for Obesity
Russ P. Lopez
Obesity 15; 2111-2119; doi:10.1038/oby.2007.251

FACT: Lack of seatbelt use can be added to the list of risk factors associated with obesity.

BMI and Seatbelt Use
David G. Schlundt, Nathaniel C. Briggs, Stephania T. Miller, Carlotta M. Arthur and Irwin A. Goldzweig
Obesity 15; 2541-2545; doi:10.1038/oby.2007.303

FICTION: Women in their first year of college have a 48% chance of gaining the "freshman 15."

Freshman 15: Fact or Fiction?
Michelle L. Morrow, Kristiann C. Heesch, Mary K. Dinger, Holly R. Hull, Allen W. Kneehans, David A. Fields
Obesity 14; 1438-1443; doi:10.1038/oby.2006.163

FACT: Listen to your heart. If you're obese, you could be at risk of developing cardiovascular disease and diabetes.

Relationship of Metabolic Risk Factors and Development of Cardiovascular Disease and Diabetes
Steven M. Haffner
Obesity 14; 121S-127S; doi:10.1038/oby.2006.291

Monday, March 23, 2009

AIM: End-of-life discussions drive down treatment costs, improve quality of life

Moral of the story: If you have a terminal illness discuss end-of-life decisions with your physician. You will be thankful in many ways as you will be on the same page as your doctor and painful, intensive treatments may be forgone for more comfortable arrangements.

AIM: End-of-life discussions drive down treatment costs
Daily Briefing - The Advisory Board Company
03/11/2009

Terminally ill patients who discussed end-of-life (EOL) care with their physicians had significantly lower health care costs and were more likely to have a better quality of life (QOL) in their final week of life compared with patients who did not have these conversations, according to a study published this week in the Archives of Internal Medicine (AIM). For the study, researchers from the Boston-based Dana-Farber Cancer Institute and colleagues followed a cohort of 627 patients with advanced cancer who were recruited for the longitudinal, multi-institutional Coping With Cancer Study between September 2002 and December 2007. At baseline—on average, six months before death—188 of 603 participants reported they had EOL discussions with their physicians. According to the findings, patients who had these discussions were more likely than their counterparts to acknowledge that they were terminally ill and report a desire to avoid dying in an ICU; patients who had EOL discussions were also less likely to prefer that their physicians take aggressive measures to extend life for a few days. As a result, the cost of care in the final week of life for patients who had discussed EOL goals with physicians averaged 35.7% lower (at an average of $1,876) than the cost of care for patients who did not have an EOL dialogue with their physicians, whose care during their final weeks of life averaged $2,917, according to aggregate costs of care determined using data from the 2004 Nationwide Inpatient Sample.

Additionally, higher costs of treatment in the final week of life were not associated with better outcomes; rather, high-cost patients experienced a worse quality of death, as reported by their caregivers. Noting that 30% of annual Medicare expenditures are attributed to the 5% of beneficiaries who die, and that about one-third of the expenditures in the last year of life are spent in the last month—mostly on life-sustaining care—the study’s authors suggest that EOL discussions between patients and providers may be an effective approach to curtailing medical care expenditures while improving patients’ quality of life and death. Specifically, the authors assert that if the “national proportion of individuals reporting EOL discussions” with health care providers increased to 50%, the cost difference between EOL and non-EOL patients could top $76 million nationally, based on the total number of U.S. cancer deaths annually. To that end, the authors support the adoption of strategies to “promote increased communication,” including direct reimbursement for EOL discussions, improved physician education regarding EOL communication, and expansion of hospital palliative care programs. Additionally, the authors suggest that oncologists and palliative care physicians co-manage care of patients with late-stage cancer.

STUDY FINDS END-OF-LIFE COSTS HIGHER AMONG BLACK, HISPANIC PATIENTS
In another study published in AIM, researchers from the Boston University School of Medicine and colleagues analyzed records of of more than 158,000 Medicare beneficiaries who died in 2001, finding that black and Hispanic patients have substantially higher EOL costs than white patients. Specifically, the mean cost of care for white patients averaged $20,166 across the last six months of life, compared with $26,704 for black patients and $31,702 for Hispanic patients. Although the study did not examine the direct cause of treatment cost disparities, the researchers attributed nearly 85% of the higher costs for non-white patients to greater use of ICU care and intensive procedures. According to the CMO of the American Cancer Society, higher utilization of life-extending procedures among minority patients may stem in part from the fact that minority populations are less likely to receive preventive care and establish long-term relationships with physicians (Zhang et al., AIM, 3/9 [subscription required]; Hanchate et al., AIM, 3/9 [subscription required]; Tanner, Associated Press/Los Angeles Times, 3/9; Stern, Reuters, 3/9; Smith, MedPage Today, 3/9).

Friday, January 23, 2009

WomenHeart Series: Depression and the Heart

Moral of the Story: One area of heart health that has been garnering a lot of attention recently in physician circles is the link between depression and cardiovascular disease. This is an in depth discussion about the clinical relationship, which is still unclear, between the two and what screening and preventive actions should be taken. This is specifically about women, however the relationship holds true for men as well.

http://www.theheart.org/article/921585.do

WomenHeart Series: Depression and the Heart
Depression is common among patients with cardiovascular disease (CVD), particularly women. Clinical depression and heightened depressive symptoms have been associated with adverse outcomes in both male and female cardiac patients. The exact mechanisms by which depression affects outcome remain to be elucidated and there is some debate over whether depression precedes or follows cardiac events. Even so, a 2008 AHA Science Advisory supports the need for screening and treating depression in patients with coronary heart disease. Our expert panel discusses the links between depression and CVD and how screening and treatment for depression can be integrated into clinical practice.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate.
SPONSORSHIP STATEMENT
This program is developed in conjunction with WomenHeart: The National Coalition for Women with Heart Disease.
Purpose / goal
The purpose of this activity is to educate clinicians to recognize and treat depression in patients with cardiovascular disease.
Target audience
This program is intended for cardiologists, primary care physicians and other healthcare providers involved in the management of patients with cardiovascular disease.
Educational objectives
At the conclusion of this program, participants will be able to:
Outline the clinical significance of depression in patients with CVD
Review data on the treatment of depression and CV risk
Summarize guidelines for the screening and treatment of depression in patients with CVD
Accreditation statement
Medscape is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Medscape designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Each participant should only claim credit commensurate with the extent of his/her participation in the activity. For questions or assistance, please contact CME@medscape.net